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A B S T R A C T
Objectives: Stage I non-small cell lung cancer (NSCLC) can be treated with either Stereotactic Body Radiotherapy
(SBRT) or Video Assisted Thoracic Surgery (VATS) resection. To support decision making, not only the impact on
survival needs to be taken into account, but also on quality of life, costs and cost-eﬀectiveness. Therefore, we
performed a cost-eﬀectiveness analysis comparing SBRT to VATS resection with respect to quality adjusted life
years (QALY) lived and costs in operable stage I NSCLC.
Materials and methods: Patient level and aggregate data from eight Dutch databases were used to estimate costs,
health utilities, recurrence free and overall survival. Propensity score matching was used to minimize selection
bias in these studies. A microsimulation model predicting lifetime outcomes after treatment in stage I NSCLC
patients was used for the cost-eﬀectiveness analysis.
Model outcomes for the two treatments were overall survival, QALYs, and total costs. We used a Dutch health
care perspective with 1.5 % discounting for health eﬀects, and 4 % discounting for costs, using 2018 cost data.
The impact of model parameter uncertainty was assessed with deterministic and probabilistic sensitivity ana-
lyses.
Results: Patients receiving either VATS resection or SBRT were estimated to live 5.81 and 5.86 discounted
QALYs, respectively. Average discounted lifetime costs in the VATS group were €29,269 versus €21,175 for
SBRT. Diﬀerence in 90-day excess mortality between SBRT and VATS resection was the main driver for the
diﬀerence in QALYs. SBRT was dominant in at least 74 % of the probabilistic simulations.
Conclusion: Using a microsimulation model to combine available evidence on survival, costs, and health utilities
in a cost-eﬀectiveness analysis for stage I NSCLC led to the conclusion that SBRT dominates VATS resection in
the majority of simulations.
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1. Introduction
Stage I Non-Small Cell Lung Cancer (NSCLC) has a relatively good
prognosis of 81 % (stage IA) or 73 % (stage IB) 5-year survival fol-
lowing curative treatments [1]. The most commonly used procedures
follow current guidelines, which suggest operable patients should pre-
ferably be treated with the appropriate thoracoscopic resection tech-
nique with Video Assisted Thoracic Surgery (VATS), while Stereotactic
Body Radiation Therapy (SBRT) is preferred in inoperable patients
[2–4]. These guidelines are based on current evidence, although there is
disagreement whether there is equipoise for operable patients between
SBRT and VATS resection.
Randomized controlled trials (RCTs) are seen as the highest quality
of evidence, because the randomization process can prevent bias [5].
Some RCTs that compared SBRT to VATS resection in operable patients
have been discontinued due to low patient accrual [6–8]. A pooled
analysis of two discontinued RCTs suggested equal eﬀectiveness, al-
though small sample size and short follow-up prohibited deﬁnitive
conclusions [9]. The POSTLIV and VALOR RCTs on clearly operable
NSCLC patients are expected to publish their results in 2026 [10].
As a result, most of the available data on VATS resection and SBRT
is observational, which has inherently a high risk for selection bias.
Healthier patients who are considered operable often receive surgery,
resulting in diﬀerences in the case-mix between VATS and SBRT pa-
tients. Selection bias has been addressed with propensity score
matching, but this often leads to small sample sizes. A pooled meta-
analysis of propensity score matched data showed no signiﬁcant dif-
ferences in cancer speciﬁc survival between the two treatment options
[11].
When the diﬀerences in recurrence-free survival (RFS) and overall
survival (OS) between the treatments are small, factors such as quality
of life and costs become important to determine the optimal treatment
choice. In a cost-eﬀectiveness analysis (CEA), relevant health outcomes
and associated costs are integrated to allow rational deliberation be-
tween treatments. This type of analysis is increasingly used to formulate
guidelines and make reimbursement decisions.
Two CEAs that have thus far been performed to compare SBRT to
surgery presented contradictory results. Shah et al. concluded that lo-
bectomy was dominant in clearly operable patients, while Paix et al.
found SBRT to be dominant [12,13]. Both studies have their limitations,
and no clear conclusions can currently be drawn.
In this paper, we present a Dutch cost-eﬀectiveness analysis com-
paring VATS resection and SBRT in stage I NSCLC, bringing together
evidence on eﬀectiveness, quality of life and costs in a microsimulation
model.
2. Methods
2.1. Concept of the microsimulation model
A microsimulation model was developed for the purpose of this
CEA. The model simulates underlying tumor growth to determine RFS
and OS for each patient [14,15]. The most important assumptions made
in the development of the microsimulation model are:
1 After curative treatment of the primary tumor, a proportion Pmetastatic
Table 1
Parameters used.
Parameter Mean Value 95 % CI Range Distribution Source
Tumor growth model parameters
Pmetastatic 0.375 – – [16,17]
λdetectable (detectability hazard) 0.0016 days−1 0.0013–0.0020 Normal Calibration [16,17,18]
λsymptom (symptom hazard) 0.00061 days−1 0.00042–0.00081 Normal Calibration [18,19,20]
βlethal (lethal volume threshold) 10.0 cm3 0.8–118 Lognormal Calibration [16,17]
βsystemic (eﬀect of systemic treatment on tumor volume) 2.05 1.91–2.20 Normal Calibration [21]
VDT (volume doubling time) 121 days−1 48–458 Truncated exponential [18]
Mtotal (total number of metastases) 8.22 0–42 Truncated normal [18]
R (size ratio of metastases) 0.90 0.66–0.99 Beta [18]
Probabilities for receiving treatment
Padjuvant 40-69 0.674 0.652–0.695 Normal [22]
Padjuvant 70-79 0.528 0.494–0.563 Normal [22]
Padjuvant 80-99 0.275 0.174–0.376 Normal [22]
Psystemic 40-69 0.708 0.702–0.714 Normal [22]
Psystemic 70-79 0.475 0.466–0.484 Normal [22]
Psystemic 80-99 0.194 0.182–0.207 Normal [22]
PVATS RWD 0.8141–0.0053 * age – – [22]
Excess mortality
Excess mortality VATS 0.005 0.002–0.063 Trunc. Normal Propensity matched [23]
Excess mortality Systemic 0.023 0.007–0.051 Trunc. Normal [24]
HRDOC 1.0 0.90–1.10 Trunc. Normal [25,26]
HRinoperable 2.3551 – – [27,28]
Health Utilities
VATS 0.725 HRQoL 0.669–0.779 Normal Propensity matched [29]
SBRT 0.789 HRQoL 0.732–0.842 Normal Propensity matched [29]
RFS 0.752 HRQoL 0.691–0.811 Normal Propensity matched [29]
Systemic therapy 0.561 HRQoL 0.468–0.654 Normal Societal based [30,31]
Post recurrence 0.653 HRQoL 0.610–0.697 Normal Societal based [31]
Last months 0.307 HRQoL 0.141–0.473 Normal Societal based [31]
Costs
Baseline costs VATS €21,052 6916.11–52,394.52 Lognormal [32]
Baseline costs SBRT €12,917 3707.50–32,980.88 Lognormal [32]
Post recurrence costs €188,076 2759.36–66,364.83 Lognormal [32]
Surveillance scan costs €266 – – Deﬁnition [32]
Model parameters used. These are the most important model parameters for the current study. The 95 % conﬁdence intervals in this table were used for the univariate
sensitivity analyses, and the distributions were used for the probabilistic sensitivity analysis. VDT: volume doubling time; VATS: Video Assisted Thoracic Surgery;
SBRT: Stereotactic Body Radiotherapy; RFS: recurrence free survival. HRDOC is a relative change in life expectancy (DOC) used in the sensitivity analyses. HRinoperable
is the pooled estimated change in life expectancy for inoperable SBRT patients in the real-world setting.
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of patients has a number of undetectable micro-metastases.
2 Micro-metastases grow exponentially, with a tumor volume dou-
bling time, which can be reduced by systemic treatment after de-
tection of recurrent disease.
3 All metastases below the minimum detectable size (5 mm diameter)
cannot be detected by a surveillance scan or become symptomatic.
4 Death of Disease (DOD) occurs when the total metastatic volume
reaches the lethal threshold. DOD is considered to be independent of
age, sex and other patient and tumor characteristics.
5 The model uses competitive risks to determine the time of detection
of metastases and time of death.
The most important parameters for this cost-eﬀectiveness evalua-
tion are found in Table 1. The model was programmed in C++, and
analyzed by Microsoft Excel Professional plus 2016 and IBM SPSS sta-
tistics version 22.
Fig. 1 depicts a ﬂowchart of the model, consisting of two parts that
closely interact. The disease course determines RFS and OS, and the
clinical pathway keeps track of the costs and Quality-adjusted Life
Years (QALYs) of each treatment plan.
Simulations start with generating a hypothetical RCT population of
100.000 operable stage I NSCLC patients. For this purpose, a life table
for the simulated stage I NSCLC population is constructed, containing
statistics on age, sex, and remaining life-years until death due to other
causes (DOC) than cancer, adjusted for smoking (Appendix). A pro-
portion of the stage I NSCLC population (Table 1) has undetected me-
tastases after treatment of their primary tumor. The remaining patients
cannot get recurrences or die of NSCLC. Subsequently, patients are
randomly assigned to VATS resection or SBRT and the transition-times
for transitions 1–4 (Fig. 1A) are drawn. Recurrences can either be
detected symptomatically or with a surveillance scan at 3, 6, 12, 18, 24,
36, 48 or 60 months. At the same time, the clinical pathway model
keeps track of the costs of additional treatments and scans for each
patient, and their QALYs.
Many model details and the mathematical functions that determine
the model can be found in the appendix.
2.2. Patient level data and calibration
The RFS and OS transition rates (2 and 3 of Fig. 1) were calibrated
to patient level RFS and OS data. For this purpose, data of stage I NSCLC
patients curatively treated between 2003 and 2013 with SBRT or be-
tween 2007 and 2013 with VATS resection was obtained from two
Dutch studies [16,17]. Diagnosis was made on basis of PET-CT scans,
with or without histological conﬁrmation. Patients were excluded if
they had cTNM stage≥ II, ECOG performance score ≥ 2, a second
primary tumor or history of previous cancer. Diﬀerent types of VATS
were included consisting for 90 % of lobectomy, and the other 10 % of
bilobectomy, sleeve - and sublobar resection. Patients from both studies
were pooled and 1:1 propensity score matched. Before matching, in-
vestigators were blinded by temporarily removing the pathological
stage as well as clinical outcome variables from the dataset. The pro-
pensity score was calculated using a cox-regression model that included
FEV% and tumor diameter (see Appendix). The resulting cohort in-
cluded 242 patients.
A log-rank test showed no diﬀerence in RFS and OS between VATS
and SBRT (p=0.68 and p=0.76), therefore underlying tumor growth
is assumed to be the same for VATS and SBRT, and it was decided to
pool the patients before calibration (Fig. 2 and Appendix Fig. 2).
Calibration was performed in the order in which the outcomes
Fig. 1. Flowchart of micro-simulation model. The model consists of two parts, on model part simulating the underlying disease, and one part simulating the clinical
consequences.
The two parts interact and jointly determine the (recurrence-free) survival and quality of life of the patients in the model. The patients’ age, sex, baseline treatment
and underlying tumor growth inﬂuence the state transitions in the model. Some state transitions are numbered as a reference for the article main text. Transitions are
not ﬁxed probabilities, but modeled as competitive risks, and rates do therefore change in time.
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inﬂuence each other. First, RFS was used to calibrate the rate at which
metastases become detectable (λdetectable). Secondly, the symptomatic
detection rate (λsymptom) was calibrated to the proportion of patients
with symptomatic detection of recurrences [19,20]. Thirdly, the lethal
tumor burden (βlethal) was calibrated to the OS of patients without
systemic therapy for recurrent disease. Finally, the eﬀect of systemic
therapy on survival (βsystemic) was calibrated to the OS of patients with
systemic therapy for recurrent disease. Additional information on these
procedures can be found in the appendix.
2.3. Systemic therapy
After calibration of βlethal and βsystemic, age-dependent probabilities
to receive adjuvant or systemic therapy for the primary tumor or re-
currences were added to the model. These probabilities were speciﬁed
in age groups, of 40–69, 70–79, and 80–99 years, because within these
groups, treatment probability was similar over the age range. The Dutch
cancer registry data was used to estimate the probabilities [22].
2.4. Excess mortality
The excess mortality of VATS resection over SBRT as shown in
transition 4 of Fig. 1 was simulated using the observed diﬀerence in the
90-day post-treatment mortality between VATS resection and SBRT,
based on statistics reported by Stokes et al. [23]. For systemic therapy,
excess mortality was assumed to be the diﬀerence in the 30-day death
rate for systemic treatment and the DOC rate, using the weighted
average over age and gender groups [24].
2.5. Health utilities
The health utilities were taken from a previous study [29]. The
baseline treatment is assumed to aﬀect health utilities for up to 3
months. After that, a treatment independent health utility was used to
weight the time before a recurrence, and after recurrent disease till
death.
Health utility decrements for adjuvant and post recurrence systemic
therapy are assumed, lasting 3 months from the start of treatment.
These were calculated by multiplying the frequencies of adverse events
reported by Rittmeyer et al. with the corresponding health utilities
decrements reported by Nafees et al. [30,33].
Default health utility in the post recurrence period was assumed to
be equal to the reported health utility in stable disease without side
eﬀects [33], although health utility was assumed to be lowered in the
last 3 months before death. The latter health utility was assumed to be
equal to the health utility reported for progressive disease with high
levels of symptoms [34,35].
2.6. Costs
Costs were derived from a Dutch 2012 costing study in NSCLC by
selecting stage I SBRT and VATS patients from the costing study data-
base [32]. All costs were inﬂated to 2018 according to the Dutch health
economic guidelines [36].
Several types of costs were analyzed separately for patients re-
ceiving VATS resection or SBRT and pooled into a single parameter
describing the baseline treatment costs of VATS and SBRT, respectively
(Appendix).
During RFS, €26,617 was added for each additional surveillance
scan according to the Dutch surveillance schedule [3]. The average
costs after detection of a recurrence were assumed to be equal to the
average total costs in stage IV [32].
2.7. Base case simulation
For the simulated cohort, the clinical pathway of the model (Fig. 1)
keeps track of the time of recurrence, time of death, cause of death, and
both discounted and undiscounted life-years (LYs), QALYs, and total
costs for each patient. Subsequently, the population average is calcu-
lated. The Dutch 1.5 % discount rate for costs and 4 % for eﬀects were
used for the base case, and the 3 % WHO rates were used for com-
parison of the model outcomes to other studies [36,37].
2.8. Additional analyses
Univariate sensitivity analyses were performed by repeating the
base-case simulation with each one of the parameters shown in Table 1
set to their upper and lower limits of 95 % CIs respectively.
A probabilistic sensitivity analysis was performed with all para-
meters used in the univariate sensitivity analysis using distributions
shown in Table 1. 10,000 simulations were run using a Latin hypercube
algorithm [38].
The appendix contains the following additional analyses: a valida-
tion experiment using real world data, the eﬀect of age on the out-
comes, and the eﬀect of the metastatic prevalence.
3. Results
3.1. Health outcomes
Average undiscounted LYs lived are 8.51 for VATS resection and
8.55 for SBRT, and the average undiscounted QALYs are 6.70 for VATS
resection and 6.75 for SBRT. Discounted outcomes with a 1.5 % dis-
count rate are 5.81 discounted QALYs for VATS resection and 5.86
QALYs for SBRT. When using WHO 3 % discount rates, the resulting
QALYs are 5.26 for VATS resection and 5.31 for SBRT.
3.2. Costs
In the base case scenario, the average undiscounted costs of VATS
resection are €29,269 versus €21,175 for SBRT. After treatment of the
primary tumor, costs in the VATS resection and SBRT groups are the
same. Further analysis reveals that hospital costs are decisive for the
Fig. 2. Recurrence free survival of the patient populations and the calibrated
model. Two Dutch datasets were pooled to obtain patient level data for VATS
(dark grey) and SBRT (light grey). These patients were 1:1 propensity matched
to minimize confounding. The resulting survival curves showed minimal dif-
ferences (log rank 0.68). Subsequently, the VATS and SBRT patients were
pooled and used for calibration of the underlying tumor growth model (black).
(For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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diﬀerence in baseline costs (Appendix). Hospital costs comprise 45 % of
the total baseline costs for VATS resection versus 17 % for SBRT, and
are also the largest contributor to the variation in costs between pa-
tients. Discounted costs of VATS resection are €28,805 versus €20,710
for SBRT when a 4 % discount rate was used, and €28,877 for VATS
resection and €20,782 for SBRT when a 3 % discount rate was used.
3.3. Cost-eﬀectiveness
SBRT dominates VATS resection in the base-case scenario, although
the average diﬀerence in QALYs of 0.05 between VATS resection and
SBRT is small. Average diﬀerence in discounted costs is −€8,095. The
incremental cost-eﬀectiveness ratio (ICER) is thus −162,334 €/QALY.
Note, however, that negative ICERs should be carefully interpreted, as
negative ICERs are in in principle ambiguous; they can refer to a less
eﬀective and more expensive treatment, or a more eﬀective and less
expensive treatment, which is the case for SBRT here.
3.4. Sensitivity analyses
Univariate sensitivity analyses showed that the ICER becomes po-
sitive when SBRT is more expensive than VATS resection (Fig. 3 and
Appendix Fig. 6). The model-predicted cost diﬀerence between VATS
resection and SBRT is most sensitive to the baseline costs of VATS re-
section and SBRT.
The diﬀerence in QALYs is determined by the VATS excess mor-
tality, and the health utility parameters for SBRT, VATS and systemic
therapy. No scenarios exist where VATS resection is more eﬀective
when only a single parameter is changed within its 95 % conﬁdence
interval (Appendix Fig. 6).
Fig. 4 depicts the diﬀerence in discounted QALYs and costs between
VATS resection and SBRT for 10.000 probabilistic draws, each simu-
lating 100.000 patients. The ﬁgure shows that SBRT is more eﬀective
and less expensive than VATS resection in 68.1 % of the simulations
[39]. Likewise, VATS resection is more eﬀective and less expensive in
6.2 % of the simulations. The cost-eﬀective strategy in the other two
trade-oﬀ quadrants is determined by the willingness to pay threshold. A
€50.000 threshold was used according to the Dutch guidelines and the
proportional shortfall method [36]. Using this threshold, SBRT is cost-
eﬀective in 82 % of the simulations. Depending on the willingness to
pay threshold SBRT is dominant in at least 74 % up to 94 % of the
simulations shown by the cost-eﬀectiveness acceptability curve (Fig. 5).
4. Conclusion and discussion
This cost-eﬀectiveness analysis of SBRT versus VATS resection in
stage I NSCLC patients found that SBRT is slightly more eﬀective (0.05
QALYs), and less expensive (-€8,095) than VATS. Probabilistic sensi-
tivity analyses (PSA) showed that SBRT is the most cost-eﬀective option
in at least 74 % of the simulations depending on the willingness to pay
threshold used. The most important factors that determine the diﬀer-
ence in outcomes between SBRT and VATS resection are related to the
baseline treatment. Excess mortality and the negative eﬀects of treat-
ment on health utility are important factors that cause the diﬀerence in
QALYs. Hospital and intensive care use are the main drivers for cost
diﬀerences between SBRT and VATS.
These ﬁndings are relevant for both clinicians and policy makers.
There has been an ongoing debate on the use of SBRT in stage I NSCLC
[40]. When SBRT was introduced for treatment of tumors, surgery was
widely considered the best curative treatment [41]. SBRT was ﬁrst
tested on inoperable patients, and has become the recommended
treatment in this group, leading to survival improvements. However,
the survival of inoperable patients was lower than operable patients,
and made it diﬃcult to enroll operable patients into RCTs to test
equivalence of both treatments [9,42].
Without RCT data available, lower levels of evidence such as pro-
pensity-score matched comparisons are still accumulating, and the
general opinion on potential equivalence of both options is shifting. At
the same time, an increase in the usage of SBRT is observable [43].
Cost-eﬀectiveness analyses can contribute to guideline adaptations and
to reimbursement decisions. Against that background, we performed
this cost-eﬀectiveness study, essentially demonstrating that both treat-
ment options result in similar patient outcomes, with a small QALY
beneﬁt for SBRT, and at a small decrease in costs.
The cost-eﬀectiveness of SBRT versus surgery has been analyzed in
the past by Paix et al., and Shah et al. [12,13]. Paix et al. found 16.35
and 15.80 discounted QALYs for SBRT and surgery respectively, using a
pooled dataset of two RCTs containing 57 medically operable patients
[9]. This is signiﬁcantly higher than the QALYs estimated in this study
or found by Shah et al. These QALYs are also much higher than we
would expect from the clinical practice.
Shah et al. found a 0.68 QALY diﬀerence between SBRT and lo-
bectomy in favor of lobectomy in clearly operable patients. The dif-
ference with our study outcomes can be explained by two things.
Firstly, Shah et al. used pathological stage to calculate recurrence rates,
introducing selection bias in the model. When the choice between VATS
resection and SBRT is made, the pathological stage is still unknown, and
a cost-eﬀectiveness comparison should therefore be based on the
Fig. 3. Tornadodiagram of univariate sensi-
tivity analyses of incremental discounted
ICERS. The bars represent the range of ICERS
found between the lower and upper value of
the 95 % CI of each parameter. SBRT is more
eﬀective than VATS in all simulated univariate
sensitivity scenarios (Appendix Figure 6). A
positive ICER in this ﬁgure therefore means
that SBRT is both more eﬀective and more
expensive than VATS. This is only the case
when the pooled baseline costs of VATS are
lower than those of SBRT.
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clinical stage.
Secondly, no disutilities were calculated for the most common
complications of lobectomy (postoperative pain and dyspnea), while
disutilities of −0.249 and −0.268 were calculated for chest wall pain
and radiation pneumonitis after SBRT. However, literature suggests
that the average disutility caused by complications should be higher for
lobectomy than for SBRT [44,45].
With respect to costs, Shah et al. presented a total lifetime health-
care costs estimate of $48.713 for VATS resection and $40.107 for SBRT
in clearly operable patients. Paix at al. report total lifetime health-care
costs of €10.727 for surgery and €9.234 for SBRT, while we found
€26.877 for VATS resection and €19.444 for SBRT. These diﬀerences
can be explained by diﬀerences between countries, and the sources of
costs taken into account. Only our study included costs for intensive
care and in-patient and outpatient hospital day costs at baseline. This
had a large impact on the diﬀerence in baseline costs between VATS
resection and SBRT in our analyses.
There are a number of limitations to this study that need to be ad-
dressed.
Firstly, we used non-randomized and retrospective data to develop
the cost-eﬀectiveness model. Ideally, cost- eﬀectiveness analyses are
performed using RCT data with long term follow-up for adequate as-
sessment of treatment eﬀects, possibly supplemented with real-world
data (RWD) on recurrence and survival patterns. RWD is often aﬀected
by selection bias, which makes it diﬃcult to correctly estimate treat-
ment eﬀects. Internationally available RCT data on SBRT and surgery,
however, consists of 58 patients only with 3 years of follow-up [9]. This
sample size is unfortunately too limited to provide an accurate assess-
ment of long-term recurrence-free and overall survival in this patient
group.
Therefore, we performed model-based simulation of an RCT in the
Dutch population based on observational studies. Although these stu-
dies are not RCT data, propensity score methods were applied to
minimize selection bias. This reduces confounding, but also decreases
the number of patients used to estimate health utilities (N= 82), excess
mortality (N=27.200), RFS and OS (N=242).
To guarantee objective matching, the investigators were blinded to
the pathological stage and outcomes of the patients during the
matching procedure. Matching on clinical stage may increase the local
recurrence rate and the presence of positive lymph nodes or benign
disease in the included patients. This will lead to increased compar-
ability between the VATS and SBRT groups. 29 VATS and 63 SBRT
patients did not have histological conﬁrmation before propensity score
matching of the survival data. Four patients in the VATS group had
benign disease, which is higher than the expected value for SBRT (see
Appendix). This may also explain why RFS and OS rates and the un-
derlying disease are very similar between SBRT and VATS groups.
The remaining parameter uncertainty was addressed in the PSA and
does not change our main study conclusions. However, in a PSA, po-
tential systematic biases, may still be present due to residual con-
founding cannot be addressed.
Secondly, it should be noted that the model was built using Dutch
databases assuming care according to the Dutch guidelines. For ex-
ample, the Dutch follow up protocol was assumed, which prescribes
Fig. 4. Probabilistic sensitivity analysis scatter
plot. This analysis shows the eﬀect of jointly
varying model parameters on the outcomes of
the model. 10.000 simulations were performed
with randomly selected model parameters
from the distributions shown in Table 1, using
a Latin Hypercube algorithm. The X-axis re-
presents the incremental discounted quality
adjusted life-years, the Y-axis represents the
incremental discounted costs. The grey dia-
monds represent all simulations with random
parameters, and the base case is depicted by
the black square. The dashed line is the Dutch
willingness to pay threshold of € 50.000 as
threshold value for one QALY [36]. (For in-
terpretation of the references to colour in this
ﬁgure legend, the reader is referred to the web
version of this article.)
Fig. 5. Cost-eﬀectiveness acceptability curve,
depicting the percentage of PSA model simu-
lations in which VATS or SBRT, respectively, is
the optimal treatment choice as a function of
the willingness to pay-threshold. If the will-
ingness to pay is zero, SBRT becomes optimal
in 74.3 % of the PSA simulations. This per-
centage increases gradually when the will-
ingness to pay increases, and eventually
reaches a plateau around 94 %. SBRT is op-
timal in 81 % of the simulations, if we use
proportional shortfall to determine the will-
ingness to pay threshold [36].
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multiple CT scans, which is not a universal model across Europe or
North America. As the nature of follow-up determines observed tran-
sition times to either relapse or detection of metastatic disease, tumor
growth rates in the model were calibrated to observed RFS, taking this
Dutch follow-up schedule into account in the modelling. In theory, the
calibrated underlying tumor growth could therefore be considered
‘universal’, but this should be validated by simulating observational
studies in countries with a diﬀerent follow-up schedule and comparing
model-predicted RFS to observed RFS. Apart from this aspect of vali-
dation, note that the precise follow-up schedule in model can be ex-
pected to have limited impact on the comparison between VATS re-
section and SBRT with respect to total costs and QALYs, as the same
schedule is followed in both arms. Nevertheless, it remains important to
realize that this economic evaluation is carried out in a Dutch context.
Thirdly, costs data were not propensity score matched (N=185).
Propensity score matching selects similar patients from both groups,
which in the case of VATS resection and SBRT would most likely mean
the unhealthier VATS patients and the healthier SBRT patients [46]. If
propensity score matching would have been feasible, this would most
likely have increased the diﬀerences in costs between VATS resection
and SBRT in the cost dataset.
Finally, more modern procedures such as single port VATS and
RATS, and MRI guided SBRT are likely to aﬀect both the costs and ef-
fects of the procedures. On these topics there is still not enough long-
term data available to make any conclusions, although diﬀerences in
QALYs and costs may become even smaller. It is therefore important to
update current economic evaluation when additional data becomes
available.
To conclude, we constructed a microsimulation model to combine
available Dutch evidence on survival, costs, and health utilities in stage
I NSCLC. We found that SBRT dominates VATS resection in the majority
of probabilistic model simulations.
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